Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer-Reference-Cited by-同舟云学术

Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer

Published:2006 Issue:2 Volume:77 Page:135-138
ISSN:0042-1138
Container-title:Urologia Internationalis
language:en
Short-container-title:Urol Int

Author:

Morote Juan,Esquena Salvador,Abascal José M.,Trilla Enrique,Cecchini Luis,Raventós Carles X.,Catalán Roberto,Reventós Jaume

Publisher

S. Karger AG

Subject

Urology

Reference14 articles.

1. Zoladex versus orchiectomy in treatmentof advanced prostate cancer: a randomized trial

2. Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic Carcinoma

3. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial

4. Randomized Open Labelled Comparative Study of the Efficacy, Safety and Tolerability of Leuprorelin Acetate 1M and 3M Depot in Patients with Advanced Prostatic Cancer

5. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relugolix in the management of prostate cancer;Expert Review of Anticancer Therapy;2022-07-27

2. Definition of Castrate Resistant Prostate Cancer: New Insights;Biomedicines;2022-03-17

3. Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer;Clinical Genitourinary Cancer;2020-04

4. Prescription switching: Rationales and risks;International Journal of Clinical Practice;2019-10-07

5. Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection;Cancer Urology;2019-01-15